Safeguard Scientifics (SFES) 10-Q 30 Apr 20 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Apr. 27, 2020
Document Information [Line Items]
Entity Registrant Name	SAFEGUARD SCIENTIFICS INC
Entity Central Index Key	0000086115
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		20,673,078
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 20,933	$ 25,028
Restricted cash	25	25
Prepaid expenses and other current assets	634	1,297
Total current assets	21,592	26,350
Property and equipment, net	2,026	2,101
Ownership interests in and advances	66,798	77,129
Other assets	1,992	1,997
Total Assets	92,408	107,577
Current Liabilities:
Accounts payable	141	39
Accrued compensation and benefits	2,096	1,364
Accrued expenses and other current liabilities	568	627
Lease liability - current	380	399
Total current liabilities	3,185	2,429
Lease liability - non-current	2,303	2,380
Other long-term liabilities	1,112	1,027
Total Liabilities	6,600	5,836
Commitments and contingencies (Note 9)
Equity:
Preferred stock, $0.10 par value; 1,000 shares authorized
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued at March 31, 2020 and December 31, 2019	2,157	2,157
Additional paid-in capital	810,827	810,856
Treasury stock, at cost; 924 and 930 shares at March 31, 2020 and December 31, 2019, respectively	(13,920)	(14,024)
Accumulated deficit	(713,231)	(697,223)
Accumulated other comprehensive loss	(25)	(25)
Total Equity	85,808	101,741
Total Liabilities and Equity	$ 92,408	$ 107,577

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Mar. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	1,000	1,000
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	83,333	83,333
Common stock, shares issued (in shares)	21,573	21,573
Treasury stock, shares (in shares)	924	930

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
General and administrative expense	$ 3,532	$ 3,057
Operating loss	(3,532)	(3,057)
Other income (loss), net	(3,567)	(1,885)
Interest income	105	873
Interest expense		(2,535)
Equity income (loss), net	(9,014)	28,267
Net income (loss) before income taxes	(16,008)	21,663
Income tax benefit (expense)	0	0
Net income (loss)	$ (16,008)	$ 21,663
Net income (loss) per share:
Basic (in dollars per share)	$ (0.77)	$ 1.05
Diluted (in dollars per share)	$ (0.77)	$ 1.05
Weighted average shares used in computing income (loss) per share:
Basic (in shares)	20,686	20,585
Diluted (in shares)	20,686	20,585

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Net income (loss)	$ (16,008)	$ 21,663
Other comprehensive income (loss):
Share of other comprehensive income (loss) of equity method interests		(31)
Total comprehensive income (loss)	$ (16,008)	$ 21,632

Condensed Consolidated Statemen

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows from Operating Activities:
Net cash used in operating activities	$ (2,551)	$ (5,782)
Cash Flows from Investing Activities:
Proceeds from sales of and distributions from ownership interests	708	41,778
Acquisitions of ownership interest	(1,000)
Advances and loans	(1,241)	(3,925)
Purchases of marketable securities		(57,243)
Proceeds from sales and maturities in marketable securities		62,235
Net cash (used in) provided by investing activities	(1,533)	42,845
Cash Flows from Financing Activities:
Tax withholdings related to equity-based awards	(11)	(149)
Net cash used in financing activities	(11)	(149)
Net change in cash, cash equivalents and restricted cash	(4,095)	36,914
Cash, cash equivalents and restricted cash at beginning of period	25,053	8,203
Cash, cash equivalents and restricted cash at end of period	$ 20,958	$ 45,117

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2018	$ (731,105)		$ 2,157	$ 810,928	$ (15,001)	$ 66,979
Balance (in shares) at Dec. 31, 2018			21,573		914
Net income (loss)	21,663					21,663
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net				7	$ (156)	(149)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)					83
Stock-based compensation expense				417		417
Balance at Mar. 31, 2019	(709,442)	(31)	$ 2,157	811,352	$ (15,157)	88,879
Balance (in shares) at Mar. 31, 2019			21,573		998
Stock options exercised, net of tax withholdings
Stock options exercised, net of tax withholdings (in shares)					1
Other comprehensive loss		(31)				(31)
Balance at Dec. 31, 2019	(697,223)	(25)	$ 2,157	810,856	$ (14,024)	101,741
Balance (in shares) at Dec. 31, 2019			21,573		930
Net income (loss)	(16,008)					(16,008)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net				(32)	$ 104	72
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)					(6)
Stock-based compensation expense				3		3
Balance at Mar. 31, 2020	$ (713,231)	$ (25)	$ 2,157	$ 810,827	$ (13,920)	$ 85,808
Balance (in shares) at Mar. 31, 2020			21,573		924

Note 1 - General

Note 1 - General	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not 10 10 2019 10 Liquidity As of March 31, 2020 $20.9 In January 2018, not The Company believes that its cash and cash equivalents at March 31, 2020 one Principles of Accounting for Ownership Interests The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests in and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss) in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09" 2014 09 December 15, 2017 December 15, 2018 December 15, 2019 July 20, 2017, not not December 31, 2019. 2020 one March 31, 2020 not

Note 2 - Ownership Interests In

Note 2 - Ownership Interests In and Advances	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	2. The following summarizes the carrying value of the Company’s ownership interests in and advances. March 31, 2020 December 31, 2019 (Unaudited - In thousands) Equity Method: Companies $ 29,289 $ 34,271 Private equity funds 271 271 29,560 34,542 Other Method: Companies 23,464 27,031 Private equity funds 453 453 23,917 27,484 Advances to companies 13,321 15,103 $ 66,798 $ 77,129 During the three March 31, 2020 $6.2 three March 31, 2020 $5.1 b8ta 19 third $12.5 3 During the three March 31, 2020 $1.5 Summarized Financial Information The following table summarizes the statement of operations data for any companies accounted for under the equity method for the three March 31, 2020 2019 one not Three Months Ended March 31, 2020 2019 (Unaudited - In thousands) Results of Operations: Revenue $ 47,414 $ 43,868 Gross profit $ 29,506 $ 24,589 Net loss $ (14,604 ) $ (33,616 )

Note 3 - Acquisitions of Owners

Note 3 - Acquisitions of Ownership Interests	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Cost and Equity Method Investments Disclosure [Text Block]	3. The following is a summary of additional deployments during the quarter ended March 31, 2020: The Company deployed an additional $1.0 $13.0 The Company funded an additional $0.6 $20.6 The Company funded an additional $0.3 $10.2 The Company funded an additional $0.2 $13.5 The Company funded an aggregate of $0.1 $16.1

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. The Company categorizes its financial instruments into a three 1 3 Level 1—Observable Level 2—Include Level 3—Unobservable no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of March 31, 2020 December 31, 2019 Carrying Fair Value Measurement at March 31, 2020 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 20,933 $ 20,933 $ — $ — Restricted cash equivalents $ 25 $ 25 $ — $ — Carrying Fair Value Measurement at December 31, 2019 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 25,028 $ 25,028 $ — $ — Restricted cash equivalents $ 25 $ 25 $ — $ — Held-to-maturity securities are carried at amortized cost, which, due to the short-term maturity of these instruments, approximates fair value using quoted prices in active markets for identical assets or liabilities defined as Level 1

Note 5 - Stock-Based Compensati

Note 5 - Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	5. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: Three Months Ended March 31, 2020 2019 (Unaudited - In thousands) General and administrative expense $ 86 $ 417 $ 86 $ 417 During the three March 31, 2020 2019 7 0

Note 6 - Income Taxes

Note 6 - Income Taxes	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	6. The Company’s consolidated income tax benefit (expense) was $0.0 three March 31, 2020 2019 not three March 31, 2020 three March 31, 2020 no

Note 7 - Net Income (Loss) Per

Note 7 - Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	7. The calculations of net income (loss) per share were as follows: Three Months Ended March 31, 2020 2019 (Unaudited - In thousands, except per share data) Basic: Net income (loss) $ (16,008 ) $ 21,663 Weighted average common shares outstanding 20,686 20,585 Net income (loss) per share $ (0.77 ) $ 1.05 Diluted: Net income (loss) for dilutive share computation $ (16,008 ) $ 21,663 Number of shares used in basic per share computation 20,686 20,585 Unvested restricted stock and DSU's — — Employee stock options — — Weighted average common shares outstanding 20,686 20,585 Net income (loss) per dilutive share $ (0.77 ) $ 1.05 Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs). If an equity method company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first Diluted earnings per share do not • At March 31, 2020 2019 0.2 0.3 $10.37 $18.45 $9.83 $19.41, • At March 31, 2020 2019 0.3 0.7

Note 8 - Segment Reporting

Note 8 - Segment Reporting	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	8. The Company operates as one March 31, 2020 13 Certain of the Company’s ownership interests as of March 31, 2020 Company Name Safeguard Primary Ownership as of March 31, 2020 Accounting Method Aktana, Inc. 17.5% Equity Clutch Holdings, Inc. 41.2% Equity Flashtalking 13.4% Other InfoBionic, Inc. 25.2% Equity Lumesis, Inc. 43.5% Equity MediaMath, Inc. 13.3% Other meQuilibrium 32.7% Equity Moxe Health Corporation 29.9% Equity Prognos Health Inc. 28.7% Equity QuanticMind, Inc. 24.2% Equity Sonobi, Inc. 21.6% Equity Syapse, Inc. 20.0% Equity T-REX Group, Inc. 13.7% Other Trice Medical, Inc. 16.6% Equity WebLinc, Inc. 38.5% Equity Zipnosis, Inc. 37.7% Equity As of March 31, 2020 December 31, 2019

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. In March 2019, June 2019. April 2026, In April 2019, June 2019. 18 three six not A summary of the Company's operating lease cash flows at March 31, 2020 Operating lease payments Expected sublease receipts (Unaudited - In thousands) 2020 (nine months ending December 31) $ 530 $ 384 2021 595 525 2022 601 540 2023 607 556 2024 613 573 2025 619 590 Thereafter 207 199 Total future minimum lease payments 3,772 $ 3,367 Less imputed interest (1,089 ) Total operating lease liabilities $ 2,683 The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not no one The Company had outstanding guarantees of $3.8 March 31, 2020 one In 2018, February 2019, January 2018. may first 1% first 1.333% no second not March 15th $0.8 March 31, 2020 The Company recorded severance expense of $1.7 three March 31, 2020 second six $2.2 March 31, 2020 In June 2011, March 2012, July 2015 one 2014 one

Note 10 - Equity

Note 10 - Equity	3 Months Ended
	Mar. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. In July 2015, $25.0 not 2019 three March 31, 2020 In February 2018, 2019 382 five 382 50 five three 382, 4.99% one not not no February 19, 2021. may no no may no

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Liquidity, Policy [Policy Text Block]	Liquidity As of March 31, 2020 $20.9 In January 2018, not The Company believes that its cash and cash equivalents at March 31, 2020 one
Investment, Policy [Policy Text Block]	Principles of Accounting for Ownership Interests The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests in and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss) in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09" 2014 09 December 15, 2017 December 15, 2018 December 15, 2019 July 20, 2017, not not December 31, 2019. 2020 one March 31, 2020 not

Note 2 - Ownership Interests _2

Note 2 - Ownership Interests In and Advances (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]	March 31, 2020 December 31, 2019 (Unaudited - In thousands) Equity Method: Companies $ 29,289 $ 34,271 Private equity funds 271 271 29,560 34,542 Other Method: Companies 23,464 27,031 Private equity funds 453 453 23,917 27,484 Advances to companies 13,321 15,103 $ 66,798 $ 77,129
Equity Method Investments [Table Text Block]	Three Months Ended March 31, 2020 2019 (Unaudited - In thousands) Results of Operations: Revenue $ 47,414 $ 43,868 Gross profit $ 29,506 $ 24,589 Net loss $ (14,604 ) $ (33,616 )

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Carrying Fair Value Measurement at March 31, 2020 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 20,933 $ 20,933 $ — $ — Restricted cash equivalents $ 25 $ 25 $ — $ — Carrying Fair Value Measurement at December 31, 2019 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 25,028 $ 25,028 $ — $ — Restricted cash equivalents $ 25 $ 25 $ — $ —

Note 5 - Stock-Based Compensa_2

Note 5 - Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Three Months Ended March 31, 2020 2019 (Unaudited - In thousands) General and administrative expense $ 86 $ 417 $ 86 $ 417

Note 7 - Net Income (Loss) Pe_2

Note 7 - Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2020 2019 (Unaudited - In thousands, except per share data) Basic: Net income (loss) $ (16,008 ) $ 21,663 Weighted average common shares outstanding 20,686 20,585 Net income (loss) per share $ (0.77 ) $ 1.05 Diluted: Net income (loss) for dilutive share computation $ (16,008 ) $ 21,663 Number of shares used in basic per share computation 20,686 20,585 Unvested restricted stock and DSU's — — Employee stock options — — Weighted average common shares outstanding 20,686 20,585 Net income (loss) per dilutive share $ (0.77 ) $ 1.05

Note 8 - Segment Reporting (Tab

Note 8 - Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Schedule of Partner Company Ownership Interest [Table Text Block]	Company Name Safeguard Primary Ownership as of March 31, 2020 Accounting Method Aktana, Inc. 17.5% Equity Clutch Holdings, Inc. 41.2% Equity Flashtalking 13.4% Other InfoBionic, Inc. 25.2% Equity Lumesis, Inc. 43.5% Equity MediaMath, Inc. 13.3% Other meQuilibrium 32.7% Equity Moxe Health Corporation 29.9% Equity Prognos Health Inc. 28.7% Equity QuanticMind, Inc. 24.2% Equity Sonobi, Inc. 21.6% Equity Syapse, Inc. 20.0% Equity T-REX Group, Inc. 13.7% Other Trice Medical, Inc. 16.6% Equity WebLinc, Inc. 38.5% Equity Zipnosis, Inc. 37.7% Equity

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Operating lease payments Expected sublease receipts (Unaudited - In thousands) 2020 (nine months ending December 31) $ 530 $ 384 2021 595 525 2022 601 540 2023 607 556 2024 613 573 2025 619 590 Thereafter 207 199 Total future minimum lease payments 3,772 $ 3,367 Less imputed interest (1,089 ) Total operating lease liabilities $ 2,683

Note 1 - General (Details Textu

Note 1 - General (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 20,933	$ 25,028

Note 2 - Ownership Interests _3

Note 2 - Ownership Interests In and Advances (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Equity Securities, FV-NI, Unrealized Gain (Loss), Total	$ 1.5
Fair Value, Inputs, Level 3 [Member]
Equity Securities, FV-NI	12.5
WebLinc, Inc and QuanticMind, Inc [Member]
Equity Method Investment, Other than Temporary Impairment	6.2
T-REX Group and Other Companies [Member]
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount	$ 5.1

Note 2 - Ownership Interests _4

Note 2 - Ownership Interests In and Advances to Partner Companies - Carrying Value of Ownership Interests (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Equity Method Companies	$ 29,560	$ 34,542
Other Companies	23,917	27,484
Advances to companies	13,321	15,103
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total	66,798	77,129
Partnership Interest [Member]
Equity Method Companies	29,289	34,271
Other Companies	23,464	27,031
Private Equity Funds [Member]
Equity Method Companies	271	271
Other Companies	$ 453	$ 453

Note 2 - Ownership Interests _5

Note 2 - Ownership Interests In and Advances - Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Revenue	$ 47,414	$ 43,868
Gross profit	29,506	24,589
Net loss	$ (14,604)	$ (33,616)

Note 3 - Acquisitions of Owne_2

Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Payments to Acquire Equity Method Investments	$ 1,000
Equity Method Investments	29,560		$ 34,542
meQuilibrium [Member]
Convertible Bridge Loan	1,000
Payments to Acquire Equity Method Investments		$ 13,000
Syapse, Inc. [Member]
Payments to Acquire Equity Method Investments	600
Equity Method Investments	20,600
Trice Medical [Member]
Convertible Bridge Loan	300
Equity Method Investments	10,200
QuanticMind [Member]
Convertible Bridge Loan	200
Equity Method Investments	13,500
WebLinc, Inc. [Member]
Convertible Bridge Loan	100
Equity Method Investments	$ 16,100

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Cash and cash equivalents	$ 20,933	$ 25,028
Restricted cash equivalents	25	25
Restricted cash equivalents	25	25
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	20,933	25,028
Restricted cash equivalents	25	25
Restricted cash equivalents	25	25
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Restricted cash equivalents
Restricted cash equivalents
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Restricted cash equivalents
Restricted cash equivalents

Note 5 - Stock-Based Compensa_3

Note 5 - Stock-Based Compensation (Details Textual) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total (in shares)	7	0

Note 5 - Stock-Based Compensa_4

Note 5 - Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Stock-based compensation expense	$ 86	$ 417
General and Administrative Expense [Member]
Stock-based compensation expense	$ 86	$ 417

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Expense (Benefit), Total	$ 0	$ 0

Note 7 - Net Income (Loss) Pe_3

Note 7 - Net Income (Loss) Per Share (Details Textual) - $ / shares shares in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.2	0.3
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 10.37	$ 9.83
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 18.45	$ 19.41
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	0.3	0.7

Note 7 - Net Income (Loss) Pe_4

Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Basic:
Net income (loss)	$ (16,008)	$ 21,663
Basic (in shares)	20,686	20,585
Basic (in dollars per share)	$ (0.77)	$ 1.05
Diluted:
Net income (loss)	$ (16,008)	$ 21,663
Basic (in shares)	20,686	20,585
Unvested restricted stock and DSU's (in shares)
Employee stock options (in shares)
Diluted (in shares)	20,686	20,585
Diluted (in dollars per share)	$ (0.77)	$ 1.05

Note 8 - Segment Reporting (Det

Note 8 - Segment Reporting (Details Textual)	3 Months Ended
	Mar. 31, 2020
Number of Operating Segments	1
Number of Non-consolidated Partner Companies	13

Note 8 - Segment Reporting - Ac

Note 8 - Segment Reporting - Active Partner Companies by Segment (Details)	Mar. 31, 2020
Aktana, Inc. [Member]
Ownership Interest Under Equity Method, Percent	17.50%
Clutch Holdings [Member]
Ownership Interest Under Equity Method, Percent	41.20%
Flashtalking [Member]
Ownership Interest Under Other Method, Percent	13.40%
InfoBionic, Inc. [Member]
Ownership Interest Under Equity Method, Percent	25.20%
Lumesis, Inc. [Member]
Ownership Interest Under Equity Method, Percent	43.50%
MediaMath, Inc. [Member]
Ownership Interest Under Other Method, Percent	13.30%
meQuilibrium [Member]
Ownership Interest Under Equity Method, Percent	32.70%
Moxe Health Corporation [Member]
Ownership Interest Under Equity Method, Percent	29.90%
Prognos Health, Inc. [Member]
Ownership Interest Under Equity Method, Percent	28.70%
QuanticMind [Member]
Ownership Interest Under Equity Method, Percent	24.20%
Sonobi [Member]
Ownership Interest Under Equity Method, Percent	21.60%
Syapse, Inc. [Member]
Ownership Interest Under Equity Method, Percent	20.00%
T-Rex Group, Inc [Member]
Ownership Interest Under Other Method, Percent	13.70%
Trice Medical, Inc. [Member]
Ownership Interest Under Equity Method, Percent	16.60%
WebLinc, Inc. [Member]
Ownership Interest Under Equity Method, Percent	38.50%
Zipnosis [Member]
Ownership Interest Under Equity Method, Percent	37.70%

Note 9 - Commitments and Cont_3

Note 9 - Commitments and Contingencies (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2020USD ($)
Deferred Compensation Liability, Current and Noncurrent, Total	$ 0.8
Employee and Severance Agreement, Maximum Aggregate Exposure	2.2
Employee Severance [Member]
Restructuring Charges, Total	$ 1.7
Minimum [Member]
Long-term Incentive Plan, Bonus Pool, Percent of Proceeds Received	1.00%
Maximum [Member]
Long-term Incentive Plan, Bonus Pool, Percent of Proceeds Received	1.333%
Private Equity Funds [Member]
Guarantor Obligations, Current Carrying Value	$ 3.8

Note 9 - Commitments and Cont_4

Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) $ in Thousands	Mar. 31, 2020USD ($)
2020 (nine months ending December 31)	$ 530
2020 (nine months ending December 31)	384
2021	595
2021	525
2022	601
2022	540
2023	607
2023	556
2024	613
2024	573
2025	619
2025	590
Thereafter	207
Thereafter	199
Total future minimum lease payments	3,772
Total future minimum lease payments	3,367
Less imputed interest	(1,089)
Total operating lease liabilities	$ 2,683

Note 10 - Equity (Details Textu

Note 10 - Equity (Details Textual) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Feb. 28, 2019	Jul. 31, 2015
Stock Repurchase Program, Authorized Amount				$ 25
Treasury Stock, Shares, Acquired (in shares)	0	0
Sale of Stock, Individual Ownership, Percent, Maximum			4.99%
Preferred Stock Purchase Right to be Exchanged for Common Stock Above Maximum Ownership Threshold (in shares)			1